Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in dMMR Tumors (MATCH Subprotocol Z1D)
NCT04439214Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2016
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in malignant solid neoplasm, lymphoma, plasma cell myeloma (MM), sponsored by National Cancer Institute. Started May 2016; status: completed.
02
Drugs
03
Conditions
malignant solid neoplasmlymphomaplasma cell myeloma (MM)
Beyond the preview
Go deeper on NCT04439214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439214.